Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT05002127 Recruiting - Gastric Cancer Clinical Trials

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Start date: January 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

NCT ID: NCT05000554 Recruiting - Gastric Cancer Clinical Trials

The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer

Start date: July 2, 2021
Phase: Phase 2
Study type: Interventional

To explore the safety and efficacy of local advanced stomach cancer patients receiving new complementary treatment of PD-1 monoantiotherapy before surgery

NCT ID: NCT04999332 Recruiting - Gastric Cancer Clinical Trials

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

LOTS
Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

NCT ID: NCT04989153 Recruiting - Gastric Cancer Clinical Trials

Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Start date: March 5, 2016
Phase:
Study type: Observational [Patient Registry]

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

NCT ID: NCT04986085 Recruiting - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

NUTRIGETNE
Start date: February 24, 2021
Phase:
Study type: Observational

It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a negative impact on different parameters (quality of life, survival). So far, the studies carried out on nutrition and NET are very scarce and none has been carried out so far in Spain. Before being able to carry out nutritional intervention studies on these patients, it is necessary to know the reality of the nutritional status of patients with NETs in Spain. The main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of nutrition in NETs in the spanish population. In addition to know the epidemiological picture, it is intended to study the nutritional status from different points of view: analytical, clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to closely monitor the patients who have a higher risk of malnutrition and to propose early interventions for those, as well as the impact of their nutritional status on different parameters: survival, hospitalization, quality of life or responses to the treatments. NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated.

NCT ID: NCT04982939 Recruiting - Gastric Cancer Clinical Trials

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Start date: June 21, 2021
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma

NCT ID: NCT04972149 Recruiting - Clinical trials for Gastric Cancer Patients Undergoing Gastrectomy

Cohort Study Comparing Surgeon Stress, Utilization of Surgical Instruments, Surgical Outcomes According to Surgical Approach for Gastrectomy

Start date: May 18, 2021
Phase:
Study type: Observational

A new surgical instrument is supposed to allow surgeon to do surgery with better performance. However, the learning period before getting used to the new instruments is necessary. The surgeon's stress to overcome the learning effect and the surgical outcome was rarely assessed. The comparative analysis of surgical outcome, surgeon's stress, and utilization of instruments for gastrectomy will be performed in prospective cohort study

NCT ID: NCT04963088 Recruiting - Gastric Cancer Clinical Trials

TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma

TAXE-GC
Start date: March 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric, or Gastroesophageal Junction Carcinoma. The study includes a screening (up to 28 days), treatment (until disease progression, intolerable toxicity, or treatment withdrawal for another reason), safety follow-up (up to 30 days following last study drug treatment), and survival follow-up phase.

NCT ID: NCT04958720 Recruiting - Gastric Cancer Clinical Trials

Spanish Registry of Esophagogastric Cancer

AGAMENON
Start date: April 27, 2020
Phase:
Study type: Observational

This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.

NCT ID: NCT04957407 Recruiting - Gastric Cancer Clinical Trials

The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning

Start date: January 1, 2019
Phase:
Study type: Observational

Based on the gastric cancer database established earlier, this project explored the PG standard suitable for Chinese people, and further explored the establishment of machine learning model to stratify gastric cancer risk in the population, guide the frequency of gastroscopy screening, and extract important gastric cancer risk factors from it.Establish electronic health records of gastric organs, track the development and outcome of gastric diseases through deep learning method, in order to predict the development and outcome of gastric diseases;Then, the simulation hypothesis deductive method is used to compare the outcomes that may be caused by different lifestyles with the help of deep learning model, so as to guide patients to develop a better lifestyle and explore the establishment of health management paths for gastric cancer patients and high-risk groups in China.